FilingSEC EDGAR6-K
Immutep Refocuses efti Clinical Development Strategy Following Root Cause Analysis
· SEC accepted
Stageclinical
Filing content
The company is conducting a root cause analysis following the discontinuation of the TACTI-004 study and intends to refocus the clinical development of efti on HNSCC and STS indications.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…